Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors

Authors
Category Primary study
JournalCancer Research
Year 2017
This article has no abstract
Epistemonikos ID: 72e5759c5f1acfa9597e43379a725783e1ca6b0c
First added on: Feb 08, 2025